Teva announces availability, price of generic HIV medications

Issue: November 2020

Teva Pharmaceuticals announced the availability and price of the first generic versions of the HIV medications Truvada and Atripla.

The patent for Truvada (emtricitabine/tenofovir disoproxil fumarate; FTC/TDF) came off patent this week, Gilead Sciences previously confirmed to Healio. Gilead announced last year that the patents for FTC/TDF and the treatment Atripla (efavirenz/FTC/TDF; EFV/FTC/TDF) would expire a year early.

Hiv under a microscope — The FDA has approved the first available generic versions of Truvada and Atripla tablets to reduce risk for HIV infection.
Source: Adobe Stock

The newly available generic version of FTC/TDF is indicated for the treatment of HIV when used with other anti-HIV medicines in adults and children who weigh at least 37 pounds, and as HIV PrEP to reduce the risk for infection in adults and adolescents who weigh at least 77 pounds, Teva said.

The generic of FTC/TDF/EFV is indicated for the treatment of HIV in patients who weigh at least 88 pounds either alone as a complete regimen or in combination with other anti-HIV medicines.

“During the COVID-19 pandemic, access to treatment is more essential than ever for those who are immunocompromised and at risk of developing more severe disease,” Teva executive Brendan O’Grady, said in a press release.

Teva reported that FTC/TDF is expected to be available through retailers and wholesalers at a wholesale acquisition cost (WAC) of $48.51 per tablet, whereas EFV/FTC/TDF is expected to be available through retailers and wholesalers at a WAC of $78.86 per tablet.

Published by:

Sources/Disclosures

Collapse

Source:

Press Release

Disclosures: O’Grady reports being an employee of Teva.

Read more

Teva announces availability, price of generic HIV medications

Related Content